UCL Discovery
UCL home » Library Services » Electronic resources » UCL Discovery

Cost-effectiveness of tenofovir instead of zidovudine for use in first-line antiretroviral therapy in settings without virological monitoring.

von Wyl, V; Cambiano, V; Jordan, MR; Bertagnolio, S; Miners, A; Pillay, D; Lundgren, J; (2012) Cost-effectiveness of tenofovir instead of zidovudine for use in first-line antiretroviral therapy in settings without virological monitoring. PLoS One , 7 (8) , Article e42834. 10.1371/journal.pone.0042834. Green open access

[img]
Preview
PDF
1376958.pdf

Download (473kB)

Abstract

The most recent World Health Organization (WHO) antiretroviral treatment guidelines recommend the inclusion of zidovudine (ZDV) or tenofovir (TDF) in first-line therapy. We conducted a cost-effectiveness analysis with emphasis on emerging patterns of drug resistance upon treatment failure and their impact on second-line therapy.

Type: Article
Title: Cost-effectiveness of tenofovir instead of zidovudine for use in first-line antiretroviral therapy in settings without virological monitoring.
Location: United States
Open access status: An open access version is available from UCL Discovery
DOI: 10.1371/journal.pone.0042834
Publisher version: http://dx.doi.org/10.1371/journal.pone.0042834
Language: English
Additional information: © von Wyl et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. The research leading to these results has received partial funding from the European Community’s Seventh Framework Programme (FP7/2007–2013) under the project ‘Collaborative HIV and Anti-HIV Drug Resistance Network (CHAIN)’ – grant agreement n° 223131. VvW was supported by a Swiss National Science Foundation (SNF) Grant for Prospective Researchers (PBEZP3-125726), and MRJ has received a grant from the National Institutes of Health (NIH K23 AI074423-05). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Keywords: Adenine, Adult, Africa South of the Sahara, Anti-Retroviral Agents, Cost-Benefit Analysis, Drug Resistance, Viral, Epidemics, Female, Genotype, HIV Infections, HIV-1, Humans, Male, Middle Aged, Organophosphonates, Stochastic Processes, Treatment Outcome, Zidovudine
UCL classification: UCL > Provost and Vice Provost Offices
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Div of Infection and Immunity
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Pop Health Sciences > Institute for Global Health
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Pop Health Sciences > Institute for Global Health > Infection and Population Health
URI: https://discovery.ucl.ac.uk/id/eprint/1376958
Downloads since deposit
173Downloads
Download activity - last month
Download activity - last 12 months
Downloads by country - last 12 months

Archive Staff Only

View Item View Item